1.43
-0.15(-9.49%)
Currency In USD
| Previous Close | 1.58 |
| Open | 1.42 |
| Day High | 1.46 |
| Day Low | 1.31 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.12 |
| Volume | 1.88M |
| Average Volume | 1.41M |
| Market Cap | 14.66M |
| PE | -1.15 |
| EPS | -1.24 |
| Moving Average 50 Days | 1.61 |
| Moving Average 200 Days | 1.72 |
| Change | -0.15 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $5.66 as of September 15, 2025 at a share price of $1.385. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 5 years ago, it would be worth $121.49 as of September 15, 2025 at a share price of $1.385.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
1 hours ago
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Com
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Sep 12, 2025 1:43 PM GMT
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Com
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
GlobeNewswire Inc.
Sep 12, 2025 12:00 PM GMT
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor